{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["2(5)"],"submitter":["Sawano T"],"pubmed_abstract":["<h4>Importance</h4>Financial relationships between pharmaceutical companies and physicians can bias the conduct, findings, and reporting of clinical trials. In Japan, the valsartan scandal was a significant event: all 5 key articles on the valsartan clinical trials were retracted after the revelation of data falsification. Consequently, the Japan Pharmaceutical Manufacturers Association issued transparency guidelines, and pharmaceutical payments have been publicly disclosed since 2013. However, the distribution of payments from pharmaceutical companies among authors involved in the valsartan scandal after its revelation has not been studied to date.<h4>Objective</h4>To identify the characteristics and distribution of payments from pharmaceutical companies to researchers involved in the val"],"journal":["JAMA network open"],"pagination":["e193817"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC6537813"],"repository":["biostudies-literature"],"pubmed_title":["Payments From Pharmaceutical Companies to Authors Involved in the Valsartan Scandal in Japan."],"pmcid":["PMC6537813"],"pubmed_authors":["Shimada Y","Tanimoto T","Ozaki A","Sawano T","Saito H"],"additional_accession":[]},"is_claimable":false,"name":"Payments From Pharmaceutical Companies to Authors Involved in the Valsartan Scandal in Japan.","description":"<h4>Importance</h4>Financial relationships between pharmaceutical companies and physicians can bias the conduct, findings, and reporting of clinical trials. In Japan, the valsartan scandal was a significant event: all 5 key articles on the valsartan clinical trials were retracted after the revelation of data falsification. Consequently, the Japan Pharmaceutical Manufacturers Association issued transparency guidelines, and pharmaceutical payments have been publicly disclosed since 2013. However, the distribution of payments from pharmaceutical companies among authors involved in the valsartan scandal after its revelation has not been studied to date.<h4>Objective</h4>To identify the characteristics and distribution of payments from pharmaceutical companies to researchers involved in the val","dates":{"release":"2019-01-01T00:00:00Z","publication":"2019 May","modification":"2025-04-19T04:58:27.543Z","creation":"2019-07-24T07:05:31Z"},"accession":"S-EPMC6537813","cross_references":{"pubmed":["31099864"],"doi":["10.1001/jamanetworkopen.2019.3817"]}}